AI assistant
Vivesto — Delisting Announcement 2016
Jan 11, 2016
3124_rns_2016-01-11_28e6d7d9-5055-47e8-94c4-96d2399fadc9.pdf
Delisting Announcement
Open in viewerOpens in your device viewer
PRESS RELEASE
Oasmia Pharmaceutical AB (Nasdaq: OASM ) to Ring the Nasdaq Stock Market Opening Bell on January 11
New York, January 11, 2016 --- Oasmia Pharmaceutical AB (Nasdaq: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that the Company will ring the Nasdaq Opening Bell on Monday, January 11 in honor of its recent listing on the Nasdaq Capital Market.
€On behalf of the entire Oasmia team, we are honored and appreciative of the opportunity to ring the Nasdaq Opening Bell,• said Julian Aleksov, Executive Chairman of Oasmia. €We believe thehuman and animal oncology treatments we have brought to market, as well as the next-generation technologies we continue to develop, will have a profound impact on the treatment of various cancers for both patients and physicians. With our recently established US sales and marketing platform, we are confident in the continued adoption of our family of products, making us well-positioned for future growth and recognition among US security-holders.•
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live - The ceremony will begin at approximately 9:20am EST.
The Company began trading on the Nasdaq Capital Market on October 23, 2015.
For more information, please contact: Julian Aleksov, Executive Chairman Tel: +46 18 50 54 40 E-mail: julian.[email protected]
For media relations: Eric Fischgrund Founder FischTank Tel: +1 (646) 699 1414 E-mail: [email protected]
For investor relations: Robert Haag Managing Partner IRTH Communications Tel: +1 (866) 976 4784 E-mail: [email protected] 2016-01-11
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and Nasdaq Capital Market (OASM.US).
Information is also available at twitter.com/oasmia
€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 13.00, CET on January 11, 2016.•